Nirav Shah – VJRegenMed https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Thu, 09 Mar 2023 11:31:47 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png Nirav Shah – VJRegenMed https://mirror.vjregenmed.com 32 32 Safety and efficacy of LV20.19 CAR-T therapy in Richter’s transformation and R/R MCL https://mirror.vjregenmed.com/video/kdyh3c3upiq-safety-and-efficacy-of-lv20-19-car-t-therapy-in-richters-transformation-and-rr-mcl/ Thu, 09 Mar 2023 11:31:47 +0000 https://mirror.vjregenmed.com/video/kdyh3c3upiq-safety-and-efficacy-of-lv20-19-car-t-therapy-in-richters-transformation-and-rr-mcl/ Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, comments on the results of two studies evaluating the LV20.19 CAR-T product in patients with Richter’s transformation and in patients with heavily pretreated mantle cell lymphoma (MCL; NCT04186520). Out of the six patients with Richter’s transformation who were evaluated, four achieved a durable remission and the overall response rate (ORR) was 100%. Patients presented a unique toxicity profile, with a high incidence of hemophagocytic lymphohistiocytosis (HLH)-like toxicity. In MCL, eight of the 14 patients in the study met the primary endpoint, and the ORR at day 90 was 100%. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

]]> Phase I study of rapcabtagene autoleucel in patients with R/R DLBCL https://mirror.vjregenmed.com/video/tqvgxis7_pi-phase-i-study-of-rapcabtagene-autoleucel-in-patients-with-rr-dlbcl/ Thu, 09 Mar 2023 11:31:46 +0000 https://mirror.vjregenmed.com/video/tqvgxis7_pi-phase-i-study-of-rapcabtagene-autoleucel-in-patients-with-rr-dlbcl/ Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, gives an update on a Phase I study of rapcabtagene autoleucel in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Dr Shah explains that this next-generation CD19 CAR-T therapy has been manufactured using T-Charge™, which allows this product to be manufactured faster than other CAR-T therapies, thus helping it to preserve T cell stemness, decrease the dose of infused CAR-Ts, and increase its overall quality. The study identified a safe dose level for further investigations and reported low rates of cytokine release syndrome (CRS). This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

]]>